Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 16, 2023

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB–IIIA NSCLC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
J. Clin. Oncol 2023 Jan 31;[EPub Ahead of Print], RS Herbst, YL Wu, T John, C Grohe, M Majem, J Wang, T Kato, JW Goldman, K Laktionov, SW Kim, CJ Yu, HV Vu, S Lu, KY Lee, G Mukhametshina, C Akewanlop, F de Marinis, L Bonanno, M Domine, FA Shepherd, D Urban, X Huang, A Bolanos, M Stachowiak, M Tsuboi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading